Mosunetuzumab is also being evaluated in a phase 1b/2 study (NCT03671018) in combination with polatuzumab vedotin, a CD79b antibody–drug conjugate, in patients with R/R B-cell lymphoma. Here, CD79B is linked to B-cell non-Hodgkin lymphoma.